Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.12 EUR
Change Today -0.19 / -5.74%
Volume 29.3K
WL6 On Other Exchanges
As of 2:00 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

wilex ag (WL6) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/15 - €5.55
52 Week Low
01/6/15 - €1.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WILEX AG (WL6)

Related News

No related news articles were found.

wilex ag (WL6) Related Businessweek News

No Related Businessweek News Found

wilex ag (WL6) Details

WILEX AG, a biopharmaceutical company, is focuses on the development and marketing of drugs and diagnostic agents in the field of oncology. The company operates in three segments: Therapeutics (Rx), Diagnostics (Dx), and Customer Specific Research (Cx). Its primary product candidates based on antibodies and small molecule compounds comprise REDECTANE, an imaging diagnostic candidate; and MESUPRON, for the treatment of pancreatic and breast cancer. WILEX AG also provides customer-specific contract services related to a technology platform for therapeutic antibody drug conjugates; and preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. The company was formerly known as WILEX Biotechnology GmbH and changed its name to WILEX AG in February 2001. WILEX AG was founded in 1997 and is headquartered in Munich, Germany.

45 Employees
Last Reported Date: 07/15/15
Founded in 1997

wilex ag (WL6) Top Compensated Officers

Chief Financial Officer and Member of the Exe...
Total Annual Compensation: €287.2K
Head of Research & Development and Member of ...
Total Annual Compensation: €203.7K
Compensation as of Fiscal Year 2014.

wilex ag (WL6) Key Developments

Wilex AG Reports Consolidated Earnings Results for the Six Months Ended May 31, 2015

Wilex AG reported consolidated earnings results for the six months ended May 31, 2015. For the period, the company reported sales revenue of EUR 1,360,000 against EUR 1,189,000 a year ago. Operating loss was EUR 1,898,000 against EUR 4,310,000 a year ago. Loss before tax was EUR 1,896,000 against EUR 4,344,000 a year ago. Net loss for the year was EUR 1,896,000 against EUR 4,391,000 a year ago. Loss per share was EUR 0.23 against EUR 0.56 a year ago. Cash flow from operating activities was EUR 2,146,000 against EUR 6,017,000 a year ago.

Wilex AG, H1 2015 Earnings Call, Jul 14, 2015

Wilex AG, H1 2015 Earnings Call, Jul 14, 2015

Wilex AG Announces Results of Heidelberg Pharma's Research Cooperation

Wilex AG announced that pioneering study results on the Antibody Targeted Amanitin Conjugates (ATACs) technology have been published in the peer-reviewed journal Nature, in a report by the Department of Cancer Biology, University of Texas MD Anderson Cancer Center and scientists of Heidelberg Pharma, a subsidiary of WILEX. In preclinical studies, research groups from MD Anderson and Heidelberg Pharma demonstrated the extraordinary efficacy of ATAC therapeutics in the treatment of a colorectal cancer subpopulation with alterations in the status of the tumor suppressor gene TP53. The reason for these alterations is the co-deletion of one copy of TP53 and the neighbouring POLR2A gene, which codes for the ATAC-target RNA polymerase II. Such hemizygous gene status of TP53 and POLR2A leads to reduced expression of RNA polymerase II and thus the significantly higher sensitivity of cancer cells towards ATACs. In preclinical, in vitro and in vivo, studies ATACs exhibited an approximately ten times higher antitumoral activity on POLR2A hemizygous cancers compared to homozygous cancers. Initial data indicates similar gene status alterations in other tumors, making ATACs a promising therapeutic strategy for patients suffering from highly resistant malignancies. In a clinical setting the selection of patients based on TP53 or POLR2A gene status will allow the expansion of the therapeutic window of ATACs and ensure high efficacy while minimizing toxicity.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WL6:GR €3.12 EUR -0.19

WL6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WL6.
View Industry Companies

Industry Analysis


Industry Average

Valuation WL6 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WILEX AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at